Dr. OlgaBezzubova

Partner

Munique + 49.89.20.60.42.200

Olga Bezzubova is the leader of the Munich IP Practice and the Firm's European life sciences and chemistry patent prosecution group. She has extensive experience in obtaining and defending intellectual property rights for clients in the fields of pharmaceuticals, biotechnology, and diagnostics.

Olga advises on all aspects of patent prosecution and opposition, SPCs (supplementary protection certificates), patent validity, and infringement. She has successfully handled dozens of European oppositions on the patentee's and the opponent's side for companies such as BMS/Celgene, Merck, Puma, and Akebia Therapeutics in the fields of small and large molecules, including antibodies, ADCs (antibody drug conjugates), and CAR-Ts (chimeric antigen receptor T cells). Olga has represented clients in highly competitive areas of RNA (ribonucleic acid) interference (RNAi) and CRISPR/Cas gene editing (clustered regularly interspaced short palindromic repeats), was involved in invalidity and infringement proceedings related to amino acid production, and obtained SPCs for the first approved gene therapy of SMA (spinal muscular atrophy). She has experience in developing global IP strategies for established biotech companies and start-ups, as well as managing patent portfolios worldwide. Olga's unique background in physics and biology allows her to counsel clients in matters involving various aspects of cell biology, genomics, proteomics, molecular biology, food science, biopharmaceuticals, and biophysics, as well as emerging technologies at the convergence of biological and physical sciences.

Olga has authored and coauthored numerous publications in the field of molecular genetics and IP.

Experiência

  • Akebia successfully challenges European patentJones Day represented Akebia Therapeutics, Inc. in successfully challenging the validity of European Patent No. EP1463823 issued to FibroGen, Inc. in opposition proceedings before the European Patent Office ("EPO").
  • Turnstone Biologics develops patent portfolios for its oncolytic virus clinical candidateJones Day is representing Turnstone Biologics Corp. in the development of patent portfolios covering its oncolytic virus programs.
  • Astellas and Agensys prosecute patent portfolios for novel monoclonal antibody and antibody-drug conjugate immunotherapeutics useful for certain cancer treatmentsJones Day represents Astellas Pharma Inc. and its subsidiary Agensys, Inc. in prosecuting their worldwide patent portfolios related to novel monoclonal antibody and antibody-drug conjugate (ADC) immunotherapeutics for use in the treatment of a variety of cancer indications, including PADCEV®, an ADC approved by the FDA in 2019 for the treatment of metastatic bladder cancer.
  • CJ CheilJedang defends German patent infringement action by Japanese competitorJones Day represented CJ CheilJedang Corporation, a major Korean-based multinational company, in an international patent dispute with a Japanese competitor before the courts in Germany, including the Federal Supreme Court of Germany.
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Puma Biotechnology obtains dismissal of opposition against its European patent relating to treatment for gefitinib/erlotinib-resistant cancers and cancers with T790M EGFR mutationAfter nearly 10 years of opposition and appeal proceedings, on behalf of Puma Biotechnology, Inc., Jones Day obtained dismissal of an opposition against a European patent, which broadly covers the use of irreversible inhibitors for the treatment of gefitinib/erlotinib-resistant cancers, as well as cancers with the T790M EGFR mutation.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®).
  • ToolGen defends multi-party opposition at EPO relating to CRISPR/Cas9 gene editing technologyJones Day is acting for ToolGen, Inc. in defense of a multi-party opposition filed at the European Patent Office against its patent rights covering application of the revolutionary CRISPR/Cas9 gene editing technology in biotechnology, medicine, and agriculture.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
    • February 7, 2017
      Brexit and the Unitary Patent System, JD Women in IP
    • November 19, 2013
      IP Strategies for Life Science Companies: The New European System, Seminar for France Biotech
    • June 4, 2013
      Divisionals in Europe: Practical Advice
    • March 25, 2013
      Europe's New Unitary Patent and Unified Patent Court: How the introduction of the Unitary Patent and Unified Patent Court will impact your existing patent portfolio